Alembic Pharmaceuticals Limited receives 11 USFDA product approval during Q1 FY2025

Alembic Pharmaceuticals Limited has received 11 US Food & Drug Administration (USFDA) Product Approvals (Final & Tentative) during the quarter ended 30th June, 2024.

Alembic has a cumulative total of 206 ANDA approvals (179 final approvals and 27 tentative approvals) from USFDA.

Shares of Alembic Pharmaceuticals Limited was last trading in BSE at Rs. 950.00 as compared to the previous close of Rs. 976.15. The total number of shares traded during the day was 20200 in over 2108 trades.

The stock hit an intraday high of Rs. 980.80 and intraday low of 947.30. The net turnover during the day was Rs. 19433819.00.

Source : Equity Bulls

Keywords

AlembicPharmaceuticals INE901L01018 Q1FY2025 ProductApprovals USFDA